OBJECTIVES This study sought to evaluate the outcomes of drug-eluting stent treatment for femoropopliteal in-stent restenosis (ISR). BACKGROUND ISR after femoropopliteal interventions is an increasing problem. Although the role of drug-eluting stents in the treatment of coronary ISR is well defined, no published studies have examined drug-eluting stents in the treatment of femoropopliteal ISR...

Despite impressive advances in stent technology, unprotected left main coronary artery (LMCA) disease requiring revascularization remains the province of the surgeon at most institutions. In a 2007 editorial, we summarized the evolution of percutaneous coronary intervention (PCI) for LMCA disease, concluding that given the available evidence at that time, coronary artery bypass graft surgery (C...

BACKGROUND Guidelines recommend that noncardiac surgery be delayed until 30 to 45 days after bare-metal stent implantation and 1 year after drug-eluting stent implantation. METHODS AND RESULTS We used linked registry data and population-based administrative health care databases to conduct a cohort study of 8116 patients (≥40 years of age) who underwent major elective noncardiac surgery in On...

Despite impressive advances in stent technology, unprotected left main coronary artery (LMCA) disease requiring revascularization remains the province of the surgeon at most institutions. In a 2007 editorial, we summarized the evolution of percutaneous coronary intervention (PCI) for LMCA disease, concluding that given the available evidence at that time, coronary artery bypass graft surgery (C...

BACKGROUND Durable polymer coatings have been implicated in mid- and long-term adverse events after drug-eluting stent implantation. A polymer-free dual-drug sirolimus- and probucol-eluting stent and a new generation permanent polymer zotarolimus-eluting stent are recently developed technologies demonstrating encouraging results. METHODS AND RESULTS In a clinical trial with minimal exclusion ...

OBJECTIVES The aim of the current study was to compare everolimus-eluting stents (EES) with sirolimus-eluting stents (SES) in patients undergoing primary angioplasty. BACKGROUND Drug-eluting stents may offer benefits in terms of repeat revascularization. However, as shown for first-generation drug-eluting stents, they may be counterbalanced by a potential higher risk of stent thrombosis, espe...

Biodegradable stents are a promising technological development, as they temporarily support the stenotic blood vessel during its healing period, leaving no obstacle for possible future interventions and avoiding long term side effects of conventional drug eluting stents. Moreover, the biodegradable stent material forms an ideal vehicle for local drug delivery [1]. Finite element computer simula...

OBJECTIVES The authors investigated the relative safety and efficacy of different drug-eluting stents (DES) and bare metal stents (BMS) in patients with ST-segment elevation myocardial infarction (STEMI) using a network meta-analysis. BACKGROUND The relative safety of DES and BMS in patients with STEMI continues to be debated, and whether advances have been made in this regard with second-gen...

of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745–754. 23. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography Interventions, American College of Surgeons, American Dental Association, Ameri...

BACKGROUND Although drug-eluting stents have dramatically reduced the rates of restenosis and target lesion revascularization, they are associated with stent thrombosis (ST), a catastrophic event likely due to delayed endothelialization and chronic inflammation caused by the polymer and the metal scaffolds. To increase the safety and efficacy of stents, polymer-free dual drug-eluting stents (DD...